Affimed NV (AFMD)

[crudeoil24]

Affimed Sees Positive Initial Data in Lymphoma Treatment Trial
8:08 am ET April 9, 2021 (Dow Jones) Print

By Robb M. Stewart


Affimed NV said it has seen positive initial clinical data from a trial of an approach developed to treat patients with a form of lymphoma.

All four patients in the Phase 1 trial experienced significant disease reduction, with two complete responses and two partial responses, with an objective response rate of 100%, the immuno-oncology company said Friday. There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease, it added,

News of the early data sparked a rally in Affimed's shares, pushing them up 28% in premarket trading after closing at $7.89 Thursday, up 36% so far this year.

The trial is looking at cord-blood-derived natural killer cells precomplexed with innate cell engager AFM13 in patients with recurrent or refractory CD30-positive lymphomas. It is an investigator-sponsored study at the University of Texas MD Anderson Cancer Center

"These initial results indicate AFM13 may have the potential to help NK cells target and destroy cancer cells," said Andreas Harstrick, chief medical officer of Affimed. "We plan to continue to develop and customize approaches that leverage the unique and differentiating features of our ICE molecules in combination with adoptive NK cell transfer to provide options for treating a variety of hematologic and solid tumors."

The company said its study is continuing enrollment of the second dose cohort.


Write to Robb M. Stewart at [e-mail]


(END) Dow Jones Newswires